Mount Sinai Hospital

The Inner Circle Acknowledges, Alan Soroka, MD as a Pinnacle Platinum Healthcare Professional for his contributions to the field of internal medicine

Retrieved on: 
星期一, 八月 21, 2023
Bachelor of Science in Nursing, City College of New York, Education, Internal medicine, Diabetes, Catholic higher education, Health care, Physician, Inner circle, American Medical Association, Hypertension, City, MD, Mount Sinai Hospital, Patient, Health, Conditional sentence, Diagnosis, Internal, Nursing

WINDSOR LOCKS, Conn., Aug. 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Alan Soroka, MD, is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the field of internal medicine.

Key Points: 
  • WINDSOR LOCKS, Conn., Aug. 21, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Alan Soroka, MD, is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the field of internal medicine.
  • Dr. Soroka pursued higher education at The City College of New York where he earned a Bachelor of Science degree.
  • A specialist in hypertension, diabetes, and all general internal medicine issues, Dr. Soroka is a founder of HealthCare, PC.
  • Internal medicine is the medical specialty dealing with the prevention, diagnosis, and treatment of adult diseases according to the doctor.

Fat Burning During Exercise Varies Widely Between Individuals; Study reveals limitations of commercial exercise machines

Retrieved on: 
星期五, 八月 11, 2023
Exercise, CDN, Obesity, University, Metabolism, Intelligence, Mount Sinai Hospital (Manhattan), Department of Medicine – University of Pamplona, Cardiovascular disease, Mount Sinai, Doctor of Philosophy, Division, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, Tel Aviv Sourasky Medical Center, Heart rate, Weight, MPH, Medical imaging, Dietary supplement, Nutrition, RD, MD, Mount Sinai Morningside, Medicine

NEW YORK, Aug. 11, 2023 /PRNewswire-PRWeb/ -- The best heart rate for burning fat differs for each individual and often does not align with the "fat burning zone" on commercial exercise machines, Icahn School of Medicine at Mount Sinai researchers report.

Key Points: 
  • The best heart rate for burning fat differs for each individual and often does not align with the "fat burning zone" on commercial exercise machines, Icahn School of Medicine at Mount Sinai researchers report.
  • NEW YORK, Aug. 11, 2023 /PRNewswire-PRWeb/ -- The best heart rate for burning fat differs for each individual and often does not align with the "fat burning zone" on commercial exercise machines, Icahn School of Medicine at Mount Sinai researchers report.
  • "People with a goal of weight or fat loss may be interested in exercising at the intensity which allows for the maximal rate of fat burning.
  • "We hope that this work will inspire more individuals and trainers to utilize clinical exercise testing to prescribe personalized exercise routines tailored to fat loss.

Applied UV Achieves Industry Milestone: Receives First Order for Patented Disinfecting Mirrors. The Units are for Installation at a Mt. Sinai Hospital in New York

Retrieved on: 
星期三, 八月 9, 2023
Well, Infection, Intellectual property, University, University of Chicago Medical Center, Pathology, Innovation, Auris, UVC, Massachusetts General Hospital, Research, Medicine, Mount Sinai Hospital, Hospital, Trust, American Society for Microbiology, COVID-19, UV, Water, Bacteria, Health, Investment, Safety, Society, News, Vaccine, Antibiotics, Pharmaceutical industry, Microbiology, Virus

NEW YORK, NY, Aug. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Applied UV, Inc. (NASDAQ: AUVI), a pioneering force in Smart Buildings Technologies, is pleased to announce a significant accomplishment through its Sterilumen subsidiary: the Company's first purchase order for its disinfecting mirrors has recently been received.  This order is for the renowned Mt. Sinai Hospital in New York. This significant milestone represents  the successful culmination of three years of research, investment, and intellectual property (IP) development by Applied UV. Our patented UV disinfecting mirrors focus on typical sinks and adjacent areas.

Key Points: 
  • This significant milestone represents  the successful culmination of three years of research, investment, and intellectual property (IP) development by Applied UV.
  • Our patented UV disinfecting mirrors focus on typical sinks and adjacent areas.
  • Our various hospital partnerships underscore the trust and credibility we have built in the market," said Max Munn, CEO of Applied UV.
  • Prominent names like University of Chicago Medical, Mass General, and Mercy Children’s Hospital are among Applied UV's clientele.

Saluda Medical Announces Publication of Favorable Economic Analysis Demonstrating Cost-Dominance of Evoke® Closed-Loop SCS over Open-Loop SCS

Retrieved on: 
星期五, 八月 4, 2023
Science, Mount Sinai Hospital, The Clinical Journal of Pain, Assistant professor, FIPP, Medicine, MD, Patient, Landmark, SCS, Pharmaceutical industry, Dentistry

MINNEAPOLIS, Aug. 4, 2023 /PRNewswire/ -- Saluda Medical, Inc. ("Saluda Medical"), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies, today announced the publication of new health economic data in The Clinical Journal of Pain that provides the strongest ever economic case for the use of Evoke® Closed-Loop SCS with physiologic SmartLoop™ technology over open-loop SCS therapy.

Key Points: 
  • The analysis sought to determine the cost-effectiveness of using the Evoke® System over open-loop SCS for the treatment of chronic intractable pain by examining the costs and outcomes associated with each therapy.
  • Results from the analysis indicate that:
    The Evoke® System becomes cost-dominant over open-loop SCS therapy approximately two years post-implant, and;
    The Evoke® System becomes cost-saving over open-loop SCS therapy approximately 5 years post-implant.
  • "This new analysis reinforces the economic case for utilizing devices which have demonstrated long-term therapy durability.
  • "We are committed to elevating SCS therapy with the best science, clinical, and health economic evidence, and the results from this study have set a new standard demonstrating cost-dominance of closed-loop therapy over open-loop therapy," said Jim Schuermann, President and CEO of Saluda Medical.

The World Health Organization Includes the Cardiovascular Polypill Developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines

Retrieved on: 
星期三, 八月 2, 2023
Medical Supplies, Health, Other Health, Pharmaceutical, Cardiology, Biotechnology, Business development, Essential, Myocardial infarction, The New England Journal of Medicine, Atorvastatin, Ferrer, NEJM, Mount Sinai Hospital, Patient, Mortality, WHO, CNIC, Director general, World Health Organization, Essential medicines, Dietary supplement, Medical device, Pharmaceutical industry, Medicine, Ramipril

The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research (CNIC) and Ferrer has been included by the World Health Organization (WHO) in its List of Essential Medicines 1.

Key Points: 
  • The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research (CNIC) and Ferrer has been included by the World Health Organization (WHO) in its List of Essential Medicines 1.
  • This cardiovascular polypill includes three active ingredients (acetylsalicylic acid, ramipril and atorvastatin) and has been proven to be effective in preventing cardiovascular events after a heart attack, reducing mortality from cardiovascular causes by 33%.
  • This was evidenced by the SECURE 2 study, with results published in August 2022 in the New England Journal of Medicine 3 (NEJM).
  • As stated in the WHO report , “essential medicines are those that satisfy the priority health care needs of a population.

Waterfront Toronto welcomes Jack Winberg as Board Chair

Retrieved on: 
星期四, 七月 27, 2023
Diamond, BILD, Urban Development Institute of Australia, City, Corporation, Mount Sinai Hospital, Mount Sinai Hospital (Toronto), Port Lands, Quayside, Industrial design, Waterfront Toronto, Villiers Island

TORONTO, July 27, 2023 /CNW/ - Jack Winberg has been appointed Chair of the Board of Directors of Waterfront Toronto effective July 1, 2023.

Key Points: 
  • TORONTO, July 27, 2023 /CNW/ - Jack Winberg has been appointed Chair of the Board of Directors of Waterfront Toronto effective July 1, 2023.
  • He brings a range of experience and knowledge to the position following a distinguished career in law, land use, and development.
  • Mr. Winberg has served on Waterfront Toronto's Board of Directors since his appointment by the City of Toronto in June 2019.
  • Waterfront Toronto thanks Stephen Diamond for his many years of dedicated service on the Waterfront Toronto Board of Directors which concluded on June 30, 2023.

CCRM Fertility to Open State-of-the-Art Fertility Clinic and IVF Lab in Miami

Retrieved on: 
星期二, 七月 25, 2023
Cognition, Albert Einstein College of Medicine, Heart, American College of Medical Genetics and Genomics, Travel, Bioethics, University, Genetics, Walter Reed National Military Medical Center, Genomics, Parent, Teaching, University of Vermont Medical Center, OBGYN, Master, Infertility, Research, Fertilisation, Bangladesh Technical Education Board, IVF, Science, Suite, Jackson Memorial Hospital, Yeshiva University, Fertility, Fertility preservation, Mount Sinai Hospital, Patient, Freezing, Rabbinic Judaism, Menopause, Gynaecology, Faculty, Genetic testing, Medical genetics, Inova Fairfax Hospital, Reproductive medicine, Environment, Arnold, Birth control, Nursing, Obstetrics, Esplanade, Jews, Medicine

MIAMI, July 25, 2023 /PRNewswire/ -- CCRM Fertility, the global pioneer in fertility treatment, research and science, today announced expansion to South Florida with a new state-of-art fertility clinic and in vitro fertilization (IVF) lab in Miami. The clinic is located in the Esplanade at Aventura development at 19505 Biscayne Blvd., Suite 2230, in Miami, FL, 33180. CCRM Fertility of Miami is co-founded by reproductive endocrinology and infertility specialists, Dr. Jonah Bardos and Dr. Callum Potts. Both doctors are currently accepting new patients.

Key Points: 
  • MIAMI, July 25, 2023 /PRNewswire/ -- CCRM Fertility , the global pioneer in fertility treatment, research and science, today announced expansion to South Florida with a new state-of-art fertility clinic and in vitro fertilization (IVF) lab in Miami.
  • CCRM Fertility of Miami is co-founded by reproductive endocrinology and infertility specialists, Dr. Jonah Bardos and Dr. Callum Potts .
  • "There is an escalated need for high-quality, personalized fertility care in Miami," said Bob LaGalia, president and CEO of CCRM Fertility.
  • CCRM Fertility of Miami is a full-service fertility center that provides fertility testing, fertility preservation, intrauterine insemination, in vitro fertilization, preimplantation genetic testing, LGBTQ+ family-building and third-party reproduction services.

Care Partner Mobile Application Launch Party

Retrieved on: 
星期五, 七月 7, 2023
Caregiver, Education, Dementia, Research, Alzheimer Society of Ontario, Mount Sinai Hospital, Eglinton Avenue, Apple, AST, Residential care

Toronto, July 07, 2023 (GLOBE NEWSWIRE) -- On July 7th, the Alzheimer Society of Toronto will launch the Care Partner Mobile Application on both the Apple and Google Play stores with a launch party.

Key Points: 
  • Toronto, July 07, 2023 (GLOBE NEWSWIRE) -- On July 7th, the Alzheimer Society of Toronto will launch the Care Partner Mobile Application on both the Apple and Google Play stores with a launch party.
  • The Care Partner App, previously known as the Dementia Talk App – is an award-winning mobile application created by the Reitman Centre at Mount Sinai Hospital.
  • The Care Partner mobile application uses tools and resources to support the caregiver of someone living with dementia, with the goal of promoting everyone's wellbeing.
  • Caregivers or care partners of people living with dementia are invited to attend the launch party which will be held from 10 am – 12 pm at the Alzheimer Society of Toronto office at 20 Eglinton Avenue West, on the 16th floor.

New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Retrieved on: 
星期一, 六月 26, 2023
EOS, HDFN, Fetus, Umbilical cord, European Medicines Agency, Janssen, Janssen Pharmaceuticals, Patient, Memorial Hermann–Texas Medical Center, Risk, Immunoglobulin G, Disease, Infant, IUT, Neonatal Fc receptor, UNITY, Tissue, Ohio State University, Hydrops, University, Dell Medical School, Gestational age, EMA, SPRING, Diagnosis, FDA, FC, Placenta, HOUSE, Health, Maternal–fetal medicine, Child, Șaeș, Blood, Immune system, Mortality, Johnson & Johnson, Epidural hematoma, Anemia, Infection, Edema, Clinical trial, Fast Track, Mount Sinai Hospital, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Birth control, Dietary supplement

SPRING HOUSE, Pa., June 26, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive results from the proof-of-concept Phase 2 open-label UNITY clinical trial for the treatment of pregnant individuals at high risk of early-onset severe (EOS) hemolytic disease of the fetus and newborn (HDFN).1 A statistically significant (54 percent [n=7/13]) proportion of participants who received nipocalimab achieved the primary endpoint of a live birth at or after gestational age of 32 weeks without intrauterine transfusions (IUTs)1,a compared to the historic reference point of 10 percent, which was derived from published and unpublished data.2-5,b Among the seven participants who achieved the primary endpoint, the median gestational age at delivery was 37 and 1/7 weeks.6 This study demonstrates the potential for nipocalimab to help address the underlying disease mechanism of EOS HDFN.1 If approved, nipocalimab would be the first anti-neonatal Fc receptor (FcRn) treatment and the first approved non-surgical intervention for pregnancies at high risk of HDFN in the U.S.7 These data will be presented for the first time at the Fetal Medicine Foundation World Congress in Valencia, Spain on June 26, 2023.1 Janssen is planning a pivotal Phase 3 trial for nipocalimab in pregnancies at risk for severe HDFN.

Key Points: 
  • "There is a significant unmet need to help address the serious and life-threatening health consequences of HDFN.
  • "These Phase 2 UNITY data in high-risk pregnancies demonstrated the important role that nipocalimab, an FcRn blocking antibody, may play in preventing the transfer of maternal alloantibodies through the placenta, thereby offering a potential treatment option for this devastating disease."
  • A conservative benchmark of 10 percent of patients not requiring an IUT was chosen to account for uncertainties in the accuracy and representation of the underlying data.2
    d.  Dr. Kenneth Moise is a paid consultant for Janssen.
  • He has not been compensated for any media work.

Generate:Biomedicines Appoints Dr. Alexandra Snyder as Executive Vice President, Research & Development

Retrieved on: 
星期一, 六月 12, 2023
Technology, Research, Other Technology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Biomedicine, Music, Research and development, Probability, Internal medicine, Bellevue Hospital, Icahn School of Medicine at Mount Sinai, Multimedia, History, Princeton University, Snyder, Mount Sinai Hospital, Patient, Machine learning, Memorial Sloan Kettering Cancer Center, Merck, Medical device, Nursing, New York University

Generate:Biomedicines today announced that Dr. Alexandra (Alex) Snyder has been appointed to Executive Vice President, Research & Development, in addition to her current responsibilities as Chief Medical Officer, effective immediately.

Key Points: 
  • Generate:Biomedicines today announced that Dr. Alexandra (Alex) Snyder has been appointed to Executive Vice President, Research & Development, in addition to her current responsibilities as Chief Medical Officer, effective immediately.
  • In her new role, Dr. Snyder will leverage her extensive clinical and scientific experience to help the company advance its generative AI pipeline of protein therapeutics to clinical stage.
  • View the full release here: https://www.businesswire.com/news/home/20230612005121/en/
    “With Alex’s appointment to Executive Vice President, Research & Development, we stand well-positioned to accelerate our robust early-to-late-stage clinical pipeline in areas of greatest unmet medical need,” said Mike Nally, Chief Executive Officer of Generate:Biomedicines.
  • Dr. Snyder graduated from Princeton University with a degree in history and a minor in music.